ABSTRACT
The magnitude of the infection fatality risk (IFR) of SARS-CoV-2 remains under debate. Because the IFR is the number of deaths divided by the number of infected, serological studies are needed to identify asymptomatic and mild cases. Also, because ascertainment of deaths attributable to COVID-19 is often incomplete, the calculation of the IFR needs to be complemented with data on excess mortality. We used data from a nation-wide seroepidemiological study and two sources of mortality information—deaths among laboratory-confirmed COVID-19 cases and excess deaths—to estimate the range of IFR, both overall and by age and sex, in Spain.
The overall IFR ranged between 1.1% and 1.4% in men and 0.58% to 0.77% in women. The IFR increased sharply after age 50, ranging between 11.6% and 16.4% in men ≥80 years and between 4.6% and 6.5% in women ≥80 years. Our IFR estimates for SARS-CoV-2 are substantially greater than IFR estimators for seasonal influenza, justifying the implementation of special public health measures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
ENE-COVID study was funded by Spanish Ministry of Health, Institute of Health Carlos III & Spanish National Health System.No other external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of the Institute of Health Carlos III (Register number: PI 39_2020)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵‡ Collaborators are listed in the Supplementary Material
Data Availability
The manuscript includes all figures needed to replicate the IFR estimations and indicate the sources used. ENE-COVID seroprevalence figures are provided here for all sex and age groups. Data on deaths come from RENAVE and MoMo, two Spanish National Surveillance Systems. Anonymized data from these systems are available under request. The specific formulary for this purpose is provided by the Department of Communicable Diseases at the National Center for Epidemiology. Instituto de Salud Carlos III. C/ Monforte de Lemos 5 28029 Madrid. (e-mail: vigilancia.cne{at}isciii.es and mortalidad{at}isciii.es respectively). Population figures have been provided by the National Institute of Statistics and are publicly available at their website (www.ine.es).
https://portalcne.isciii.es/enecovid19/
https://momo.isciii.es/public/momo/dashboard/momo_dashboard.html
